Get notified of page updates
Enroll in Research > Research Search & Enroll Tool > PARP inhibitor (niraparib) in patients with inherited or tumor PALB2 mutations in advanced solid tumors (PAVO)
PARP inhibitor (niraparib) in patients with inherited or tumor PALB2 mutations in advanced solid tumors (PAVO)

PARP inhibitor (niraparib) in patients with inherited or tumor PALB2 mutations in advanced solid tumors (PAVO)

Clinicaltrials.gov identifier:
NCT05169437

Treatment
Any advanced or metastatic solid tumor except ovarian or prostate

Study Contact Information:

Study Contact Information:
pavo@tempus.com


PARP inhibitor (niraparib) in patients with inherited or tumor PALB2 mutations in advanced solid tumors (PAVO)

About the Study

PAVO is an Phase II study investigating if the study drug, a called (), is safe and effective for certain people who have been diagnosed with an advanced solid tumor with either an inherited or tumor mutation.

All participants will receive the study drug, . Study participants will be dosed with orally once daily throughout each 28-day cycle and be evaluated via CT or scans every 8 weeks for approximately one year. Participants will have the opportunity to report patient-reported outcomes (PROs) while on study treatment at the scan intervals.

Study Locations

For a list of study sites enrolling patients, see clinicaltrials.gov.

Lead Researchers/Study PIs and Affiliation

 

This Study is Open To:

Inclusion criteria:

  • Positive test for a pathogenic gene mutation (inherited or tumor)
  • Provide archival tissue representative of current tumor status
  • Received all standard therapies appropriate for their tumor type and of disease or, in the opinion of the Investigator, the participant would be unlikely to tolerate or derive clinically meaningful benefit from appropriate standard of care therapy, or has no satisfactory alternative treatments.
This Study is Not Open To:

People with the following are not eligible to participate

  • Ovarian or cancer
  • Inherited or tumor or mutations
  • Received prior PARP inhibitor(s) in prior lines of treatment
  • Relapsed while receiving platinum based therapy in the adjuvant/curative setting
  • Progressed within 14-18 weeks while receiving platinum based therapy in the setting